J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
Фаза 2 – изследване на ефективността и дозировката
Заболявания:
Ulcerative Colitis
Спонсор: Eli Lilly & Co.
Налично на:
БГ
Обобщение
Trial status: Authorised
The proportion of participants who achieve clinical remission with mMS at Week 12
Кой може да участва
Age group: 18-64 years, 65+ years
Gender: Female, Male
Target enrollment: 75 participants
БГ
EN